EvolVeritas Biotechnology Ltd.
Biotech company specializing in complement-targeting drug development.
Bemutatkozás
EvolVeritas Biotechnology Ltd. is a spinoff biotech company founded in 2011 by scientists studying the molecular mechanism of complement activation through structure-driven protein engineering, directed protein evolution, and enzymology. The company has received seed funding from Medical Innovation Partners and PBG FMC to conduct pre-clinical validation and set up non-GMP manufacturing. EvolVeritas is well-positioned to become a significant player in generating research tool ligands for discovering new drug targets and developing drug candidate compounds. The company owns IP rights for lead compounds and has partnerships with multinational pharma companies like Bayer and Gedeon Richter. Their research focuses on areas such as ischemia-reperfusion injuries, microvascular injury and thrombosis due to severe COVID-19 infection, treatment of IgA nephropathy, prevention and treatment of SARS-CoV-2 and influenza infections, and preventive solutions against prostate cancer metastasis.
Szolgáltatások, tevékenységek
- Development of research tool ligands for discovering new drug targets
- Development of drug candidate compounds through specific protein molecules
- Pre-clinical validation of drug candidates
- Non-GMP manufacturing of drug candidates
- Treatment of ischemic reperfusion injury
- Treatment of thrombosis
- Treatment of COVID-19
- Treatment of IgA nephropathy
- Prevention and treatment of SARS-CoV-2 infection
- Prevention and treatment of influenza infections
- Preventive solution against prostate cancer metastasis
Telephelyek és nyitvatartás
EvolVeritas Biotechnology Ltd. Budapest OfficeIroda
H-1082 Budapest, Corvin stny. 1/b. 9. em. 6.
EvolVeritas Biotechnology Ltd. Szentes OfficeIroda
H-6600 Szentes, Somogyi Béla u. 17.